Tag: immunotherapy
Prior Pneumonitis as a Risk Factor for Treatment-Associated Pneumonitis With Immune...
By Kara Nyberg, PhD
Posted: June 24, 2020
Pneumonitis is a well-known complication associated with immune checkpoint inhibitors (ICI). A collaborative effort between the U.S. Food...
Systemic Therapy for Advanced Stage Lung Cancer During the COVID-19 Pandemic
IASLC faculty members from Europe, Asia and North America will discuss systemic therapies including chemotherapy, immunotherapy, and targeted therapy for advanced-stage lung cancer during...
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC...
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD
Posted: April 16, 2020
Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of...
Doctor of Nursing Practice Project Aims to Educate Non-Oncology Providers About...
By Enza Esposito Nguyen, DNP, RN, ANP-BC
Posted: February 12, 2020
Although we continue to see many immunotherapy clinical trials mature and deliver marvelous improvements in...
Ongoing Immunotherapy Challenges Part II: Defining Benefit for Elderly Patients With...
This article is the second in a two-part series on ongoing challenges using immunotherapy in special populations. The first part of this series focused on...
Journal Radar: Robust Survival Duration Shown in NSCLC With Pembrolizumab
By Suresh Ramalingam, MD
Posted: December 11, 2019
IN REFERENCE TO: Garon EB, Hellmann MD, Rizvi NA, et al. Five-Year Overall Survival for Patients With Advanced...
Concurrent Chemoradiation Followed by Consolidation Therapy: Questions Remain Despite Transformational Data
Posted: November 12, 2019
Now that data from the PACIFIC trial have been incorporated into daily practice, similar trials are validating the results or taking...
